Abstract
The economics of biobanking is an area that has traditionally been overlooked as biospecimen resources have been developed and expanded over the past 20 years. The explosive growth of interest in biobanking, and in the value of biospecimens and data that they collect and disseminate, has led to the necessity to adopt professional standards and practices, including business plans. There are a number of factors to consider in developing a biobank business plan, and some of these issues are unique to biospecimen resources. The costs of developing and maintaining a biobank are often difficult to assess given the traditional methods of funding including centralized institutional funding. Among the approaches to developing a business plan is the assessment of such costs and implementation of a cost-recovery plan. However such plans are difficult to implement or not allowed by institutional rules, and smaller biobanks may not be in a position to devote resources to developing and implementing a business plan. A broader approach that plans for the long-term sustainability of a biobank or biobanking network within a framework that considers the size and mission of the resource is now evolving.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Vaught J (2014) Economics: the neglected “omics” of biobanking. Biopreserv Biobank 11:259
Hewitt R, Watson P (2013) Defining biobank. Biopreserv Biobank 11:209–315
Watson PH, Nussbeck SY, Carter C et al (2014) A framework for biobank sustainability. Biopreserv Biobank 12:60–68
Baird PM, Frome RJ (2005) Large-scale repository design. Cell Preserv Technol 3:256–266
Vaught J, Rogers J, Carolin T et al (2011) Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J Nat Cancer Inst Monogr 42:24–31
National Health and Medical Research Council, Australia (2016) https://www.nhmrc.gov.au/about. Accessed 23 Apr 2016
Cooperative Human Tissue Network (CHTN) (2016) US National Cancer Institute. http://www.chtn.nci.nih.gov/. Accessed 23 Apr 2016
Rogers J, Carolin T, Vaught J (2011) Biobankonomics: a taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research. J Nat Cancer Inst Monogr 42:32–38
International Society for Biological and Environmental Repositories (2012) Best practices for repositories collection, storage, retrieval, and distribution of biological materials for research. Biopreserv Biobank 10:79–161. doi:10.1089/bio.2012.1022
Vaught J, Kelly A, Hewitt R (2009) A review of international biobanks and networks: success factors and key benchmarks. Biopreserv Biobank 7:143–150
International Society for Biological and Environmental Repositories (ISBER). http://www.isber.org. Accessed 23 Apr 2016
U.S. National Cancer Institute Biorepositories and Biospecimen Research Branch (2011) Best practices for biospecimen resources. http://www.biospecimens.cancer.gov/bestpractices. Accessed 23 Apr 2016
Canadian Tissue Repository Network CTRNet (2016) https://www.ctrnet.ca/. Accessed 23 Apr 2016
Simeon-Dubach D, Watson P (2014) Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem 47(4–5):300–308. PubMed PMID: 24406300
IWGSC (2009) Scientific collections: mission-critical infrastructure for federal science agencies. A report of the Interagency Working Group on Scientific Collections (IWGSC). National Science and Technology Council, Committee on Science, Office of Science and Technology Policy, Washington. http://www.whitehouse.gov/sites/default/files/sci-collections-report-2009-rev2.pdf. Accessed 23 Apr 2016
Gunter E (1997) Biological and environmental specimen banking at the Centers for Disease Control and Prevention. Chemosphere 34:1945–1953
Fenstermacher D, Wenham R, Rollison D et al (2011) Implementing personalized medicine in a cancer center. Can J 17:528–536
Craig B, Han G, Munkin M et al (2016) Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis. Stat Methods Med Res 25(4):1303–1312. doi:10.1177/0962280213480282
European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) (2016) http://www.esbb.org. Accessed 23 Apr 2016
Matzke E, O’Donoghue S, Barnes R et al (2012) Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank 10:426–432
Kozlakidis Z, Mant C, Cason J (2012) Bridging the financial gap through providing contract services: a model for publicly funded clinical biobanks. Biopreserv Biobank 10:357–360
McDonald S, Sommerkamp K, Egan-Palmer M et al (2012) Fee-for-service as a business model of growing importance: the academic biobank experience. Biopreserv Biobank 10:421–425
Strzelecki M (2013) The economics of biobanking. Critical values. October 2013:32–35
Vaught J, Rogers J, Myers K et al (2011) An NCI perspective on creating sustainable biospecimen resources. J Nat Cancer Inst Monogr 42:1–7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Vaught, J., Watson, P.H. (2017). Economics of Biobanking. In: Hainaut, P., Vaught, J., Zatloukal, K., Pasterk, M. (eds) Biobanking of Human Biospecimens. Springer, Cham. https://doi.org/10.1007/978-3-319-55120-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-55120-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55118-0
Online ISBN: 978-3-319-55120-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)